117 related articles for article (PubMed ID: 26764527)
1. A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Maddocks K; Hertlein E; Chen TL; Wagner AJ; Ling Y; Flynn J; Phelps M; Johnson AJ; Byrd JC; Jones JA
Leuk Lymphoma; 2016 Sep; 57(9):2212-5. PubMed ID: 26764527
[No Abstract] [Full Text] [Related]
2. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
Kummar S; Gutierrez ME; Gardner ER; Chen X; Figg WD; Zajac-Kaye M; Chen M; Steinberg SM; Muir CA; Yancey MA; Horneffer YR; Juwara L; Melillo G; Ivy SP; Merino M; Neckers L; Steeg PS; Conley BA; Giaccone G; Doroshow JH; Murgo AJ
Eur J Cancer; 2010 Jan; 46(2):340-7. PubMed ID: 19945858
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia.
Lancet JE; Gojo I; Burton M; Quinn M; Tighe SM; Kersey K; Zhong Z; Albitar MX; Bhalla K; Hannah AL; Baer MR
Leukemia; 2010 Apr; 24(4):699-705. PubMed ID: 20111068
[TBL] [Abstract][Full Text] [Related]
4. Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations.
Burris HA; Berman D; Murthy B; Jones S
Cancer Chemother Pharmacol; 2011 May; 67(5):1045-54. PubMed ID: 20652703
[TBL] [Abstract][Full Text] [Related]
5. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.
Hertlein E; Wagner AJ; Jones J; Lin TS; Maddocks KJ; Towns WH; Goettl VM; Zhang X; Jarjoura D; Raymond CA; West DA; Croce CM; Byrd JC; Johnson AJ
Blood; 2010 Jul; 116(1):45-53. PubMed ID: 20351313
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.
Weigel BJ; Blaney SM; Reid JM; Safgren SL; Bagatell R; Kersey J; Neglia JP; Ivy SP; Ingle AM; Whitesell L; Gilbertson RJ; Krailo M; Ames M; Adamson PC
Clin Cancer Res; 2007 Mar; 13(6):1789-93. PubMed ID: 17363534
[TBL] [Abstract][Full Text] [Related]
7. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
Smith MA; Morton CL; Phelps DA; Kolb EA; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Wu J; Houghton PJ
Pediatr Blood Cancer; 2008 Jul; 51(1):34-41. PubMed ID: 18260120
[TBL] [Abstract][Full Text] [Related]
8. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
Bagatell R; Gore L; Egorin MJ; Ho R; Heller G; Boucher N; Zuhowski EG; Whitlock JA; Hunger SP; Narendran A; Katzenstein HM; Arceci RJ; Boklan J; Herzog CE; Whitesell L; Ivy SP; Trippett TM
Clin Cancer Res; 2007 Mar; 13(6):1783-8. PubMed ID: 17363533
[TBL] [Abstract][Full Text] [Related]
9. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
Saif MW; Erlichman C; Dragovich T; Mendelson D; Toft D; Burrows F; Storgard C; Von Hoff D
Cancer Chemother Pharmacol; 2013 May; 71(5):1345-55. PubMed ID: 23564374
[TBL] [Abstract][Full Text] [Related]
10. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Modi S; Stopeck AT; Gordon MS; Mendelson D; Solit DB; Bagatell R; Ma W; Wheler J; Rosen N; Norton L; Cropp GF; Johnson RG; Hannah AL; Hudis CA
J Clin Oncol; 2007 Dec; 25(34):5410-7. PubMed ID: 18048823
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
Ramanathan RK; Egorin MJ; Eiseman JL; Ramalingam S; Friedland D; Agarwala SS; Ivy SP; Potter DM; Chatta G; Zuhowski EG; Stoller RG; Naret C; Guo J; Belani CP
Clin Cancer Res; 2007 Mar; 13(6):1769-74. PubMed ID: 17363531
[TBL] [Abstract][Full Text] [Related]
12. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.
Richardson PG; Chanan-Khan AA; Alsina M; Albitar M; Berman D; Messina M; Mitsiades CS; Anderson KC
Br J Haematol; 2010 Aug; 150(4):438-45. PubMed ID: 20618337
[TBL] [Abstract][Full Text] [Related]
13. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors.
Jhaveri K; Miller K; Rosen L; Schneider B; Chap L; Hannah A; Zhong Z; Ma W; Hudis C; Modi S
Clin Cancer Res; 2012 Sep; 18(18):5090-8. PubMed ID: 22781552
[TBL] [Abstract][Full Text] [Related]
14. 17-DMAG-loaded nanofibrous scaffold for effective growth inhibition of lung cancer cells through targeting HSP90 gene expression.
Mellatyar H; Talaei S; Pilehvar-Soltanahmadi Y; Dadashpour M; Barzegar A; Akbarzadeh A; Zarghami N
Biomed Pharmacother; 2018 Sep; 105():1026-1032. PubMed ID: 30021337
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.
Kaufmann SH; Karp JE; Litzow MR; Mesa RA; Hogan W; Steensma DP; Flatten KS; Loegering DA; Schneider PA; Peterson KL; Maurer MJ; Smith BD; Greer J; Chen Y; Reid JM; Ivy SP; Ames MM; Adjei AA; Erlichman C; Karnitz LM
Haematologica; 2011 Nov; 96(11):1619-26. PubMed ID: 21791475
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
Walker AR; Klisovic R; Johnston JS; Jiang Y; Geyer S; Kefauver C; Binkley P; Byrd JC; Grever MR; Garzon R; Phelps MA; Marcucci G; Blum KA; Blum W
Leuk Lymphoma; 2013 Sep; 54(9):1996-2002. PubMed ID: 23256542
[TBL] [Abstract][Full Text] [Related]
17. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.
Pacey S; Gore M; Chao D; Banerji U; Larkin J; Sarker S; Owen K; Asad Y; Raynaud F; Walton M; Judson I; Workman P; Eisen T
Invest New Drugs; 2012 Feb; 30(1):341-9. PubMed ID: 20683637
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Solit DB; Ivy SP; Kopil C; Sikorski R; Morris MJ; Slovin SF; Kelly WK; DeLaCruz A; Curley T; Heller G; Larson S; Schwartz L; Egorin MJ; Rosen N; Scher HI
Clin Cancer Res; 2007 Mar; 13(6):1775-82. PubMed ID: 17363532
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.
Pacey S; Wilson RH; Walton M; Eatock MM; Hardcastle A; Zetterlund A; Arkenau HT; Moreno-Farre J; Banerji U; Roels B; Peachey H; Aherne W; de Bono JS; Raynaud F; Workman P; Judson I
Clin Cancer Res; 2011 Mar; 17(6):1561-70. PubMed ID: 21278242
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein 90 (HSP90) inhibition in acute myeloid leukemia--targeting of disease heterogeneity through direct and indirect antileukemic effects.
Bruserud Ø; Hatfield KJ; Reikvam H
Leuk Res; 2011 Sep; 35(9):1156-8. PubMed ID: 21802728
[No Abstract] [Full Text] [Related]
[Next] [New Search]
